1. Home
  2. OCUL
  3. OCUL News

Latest Ocular Therapeutix Inc. (OCUL) News on January 19, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

2 days ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
OCUL

GlobeNewswire

5 days ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation
OCUL

GlobeNewswire

11 days ago

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week
OCUL

Simply Wall St.

a month ago

Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

a month ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
OCUL

GlobeNewswire

a month ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix announces over 300 subjects randomized in SOL-1
OCUL

TipRanks

2 months ago

Ocular Therapeutix announces over 300 subjects randomized in SOL-1

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...
OCUL

GuruFocus.com

2 months ago

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
OCUL

Zacks

2 months ago

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

OCUL

Associated Press Finance

2 months ago

Ocular Therapeutix: Q3 Earnings Snapshot

OCUL

MT Newswires

2 months ago

Ocular Therapeutix Q3 Net Loss Narrows as Revenue Increases

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates
OCUL

Zacks

2 months ago

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings
OCUL

GuruFocus.com

2 months ago

What To Expect From Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
OCUL

GlobeNewswire

2 months ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

OCUL

MT Newswires

3 months ago

Scotiabank Initiates Ocular Therapeutix at Sector Outperform

OCUL

MT Newswires

3 months ago

Ocular Therapeutix Speeds Up Timeline for Phase 3 Trial of Wet AMD Therapy; Shares Rise 7% Pre-Bell

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
OCUL

Zacks

3 months ago

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at October Ophthalmology Meetings
OCUL

GlobeNewswire

3 months ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength
OCUL

Zacks

3 months ago

Here's What Could Help Ocular Therapeutix (OCUL) Maintain Its Recent Price Strength

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at September Retina Meetings
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September
OCUL

GlobeNewswire

4 months ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
OCUL

Zacks

5 months ago

Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

With 65% ownership of the shares, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is heavily dominated by institutional owners
OCUL

Simply Wall St.

5 months ago

With 65% ownership of the shares, Ocular Therapeutix, Inc. (NASDAQ:OCUL) is heavily dominated by institutional owners

OCUL

MT Newswires

5 months ago

Ocular Therapeutix Says FDA Agrees on Regulatory Path for Axpaxli in Wet AMD

OCUL

MT Newswires

5 months ago

Ocular Therapeutix's Shares Rise After Higher Q2 Revenue That Beat Forecast

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
OCUL

Zacks

5 months ago

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

OCUL

Associated Press Finance

5 months ago

Ocular Therapeutix: Q2 Earnings Snapshot

Ocular Therapeutix™ Reports Second Quarter 2024 Results
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD
OCUL

GlobeNewswire

5 months ago

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing
OCUL

Simply Wall St.

6 months ago

The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

6 months ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCUL

MT Newswires

7 months ago

Ocular Therapeutix Shares Rise After TD Cowen Upgrades Rating, Increases Price Target

OCUL

MT Newswires

7 months ago

TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7

OCUL

MT Newswires

7 months ago

Sector Update: Health Care Stocks Decrease Late Afternoon

OCUL

MT Newswires

7 months ago

Ocular Therapeutix Shares Rise Following Clinical Development Progress Report

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued
OCUL

Simply Wall St.

7 months ago

An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued

Ocular Therapeutix® to Host Investor Day on June 13, 2024
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

7 months ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OCUL

MT Newswires

8 months ago

Ocular Therapeutix Cutting 13% of Workforce

OCUL

MT Newswires

8 months ago

Piper Sandler Starts Ocular Therapeutix With Overweight Rating, $15 Price Target

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
OCUL

GuruFocus.com

8 months ago

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings

OCUL

Associated Press Finance

8 months ago

Ocular Therapeutix: Q1 Earnings Snapshot

Ocular Therapeutix™ Reports First Quarter 2024 Results
OCUL

GlobeNewswire

8 months ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL

GlobeNewswire

8 months ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
OCUL

GlobeNewswire

8 months ago

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

2 Small-Cap Growth Stocks With Room to Run
OCUL

Motley Fool

9 months ago

2 Small-Cap Growth Stocks With Room to Run

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
OCUL

Benzinga

9 months ago

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
OCUL

Zacks

9 months ago

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
OCUL

GlobeNewswire

9 months ago

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
OCUL

GlobeNewswire

10 months ago

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

OCUL

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Clearside Biomedical Inc Earnings Call

Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
OCUL

Zacks

10 months ago

Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet

Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts
OCUL

GuruFocus.com

10 months ago

Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
OCUL

Zacks

10 months ago

Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

OCUL

Associated Press Finance

10 months ago

Ocular Therapeutix: Q4 Earnings Snapshot

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
OCUL

GlobeNewswire

10 months ago

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
OCUL

GlobeNewswire

10 months ago

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors
OCUL

Barrons.com

a year ago

Criteo, Ocular Therapeutix, and More Stocks See Action From Activist Investors

Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?
OCUL

Zacks

a year ago

Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?

Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice
OCUL

Zacks

a year ago

Are You Looking for a Top Momentum Pick? Why Ocular Therapeutix (OCUL) is a Great Choice

Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
OCUL

Zacks

a year ago

Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

3 Stocks to Buy That Are Up 100% or More in 2024
OCUL

InvestorPlace

a year ago

3 Stocks to Buy That Are Up 100% or More in 2024

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade
OCUL

Zacks

a year ago

Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 64.63%: Here's is How to Trade

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
OCUL

PR Newswire

a year ago

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?
OCUL

Zacks

a year ago

Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?

Bel Fuse (BELFB) Stock Declines While Market Improves: Some Information for Investors
OCUL

Zacks

a year ago

Bel Fuse (BELFB) Stock Declines While Market Improves: Some Information for Investors

PIEDMONT OFFICE REALTY TRUST DECLARES FIRST QUARTER DIVIDEND
OCUL

GlobeNewswire

a year ago

PIEDMONT OFFICE REALTY TRUST DECLARES FIRST QUARTER DIVIDEND

Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?
OCUL

Zacks

a year ago

Does Ocular Therapeutix (OCUL) Have the Potential to Rally 134.83% as Wall Street Analysts Expect?

Enterprise Bancorp Inc (EBTC) Reports Decline in Quarterly Net Income Amidst Rising Interest Rates
OCUL

GuruFocus.com

a year ago

Enterprise Bancorp Inc (EBTC) Reports Decline in Quarterly Net Income Amidst Rising Interest Rates

Why Fisker Stock Dived by Almost 9% Today
OCUL

Motley Fool

a year ago

Why Fisker Stock Dived by Almost 9% Today

Is Navigator Holdings (NVGS) Outperforming Other Transportation Stocks This Year?
OCUL

Zacks

a year ago

Is Navigator Holdings (NVGS) Outperforming Other Transportation Stocks This Year?

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
OCUL

GlobeNewswire

a year ago

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
OCUL

Benzinga

a year ago

Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?

OCUL

Reuters

a year ago

CORRECTED-SEC probes B. Riley deals with client tied to failed hedge fund - Bloomberg News

Share on Social Networks: